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Altered expression of genes 
controlling metabolism 
characterizes the tissue response 
to immune injury in lupus
Kathryn M. Kingsmore1*, Prathyusha Bachali1, Michelle D. Catalina1,2, Andrea R. Daamen1, 
Sarah E. Heuer1,3, Robert D. Robl1, Amrie C. Grammer1,4 & Peter E. Lipsky1,4
To compare lupus pathogenesis in disparate tissues, we analyzed gene expression profiles of human 
discoid lupus erythematosus (DLE) and lupus nephritis (LN). We found common increases in myeloid 
cell-defining gene sets and decreases in genes controlling glucose and lipid metabolism in lupus-
affected skin and kidney. Regression models in DLE indicated increased glycolysis was correlated 
with keratinocyte, endothelial, and inflammatory cell transcripts, and decreased tricarboxylic (TCA) 
cycle genes were correlated with the keratinocyte signature. In LN, regression models demonstrated 
decreased glycolysis and TCA cycle genes were correlated with increased endothelial or decreased 
kidney cell transcripts, respectively. Less severe glomerular LN exhibited similar alterations in 
metabolism and tissue cell transcripts before monocyte/myeloid cell infiltration in some patients. 
Additionally, changes to mitochondrial and peroxisomal transcripts were associated with specific 
cells rather than global signal changes. Examination of murine LN gene expression demonstrated 
metabolic changes were not driven by acute exposure to type I interferon and could be restored 
after immunosuppression. Finally, expression of HAVCR1, a tubule damage marker, was negatively 
correlated with the TCA cycle signature in LN models. These results indicate that altered metabolic 
dysfunction is a common, reversible change in lupus-affected tissues and appears to reflect damage 
downstream of immunologic processes.
Systemic lupus erythematosus (SLE) is a complex autoimmune disease that affects multiple tissues within the 
body, including the skin and  kidneys1,2. Although the primary mechanisms of SLE pathogenesis involve hyper-
activity of both the innate and adaptive immune systems, evidence surrounding the involvement of perturbed 
metabolic activity has recently  emerged3–5. Whereas systemic metabolic dysregulation has been associated with 
lupus-related morbidities, such as  atherosclerosis6, the contribution of cellular metabolic abnormalities in human 
lupus-affected tissues has yet to be fully explored. Metabolic derangements in tissues and their contributions to 
disease pathology have been investigated in a number of inflammatory and rheumatic diseases. For example, 
abnormalities in mitochondrial functions contribute to immune/inflammatory skin  diseases7, and skin cells have 
been shown to upregulate the pentose phosphate pathway (PPP) under oxidative  stress8. Moreover, rheumatoid 
arthritis synoviocytes shift their metabolism to glycolysis because of local  hypoxia9 and osteoarthritis exhibited 
increased synovial tricarboxylic acid (TCA) cycle  intermediates10. Similarly, metabolic impairment has been 
found in many forms of kidney  disease11,12, including defects in fatty acid oxidation (FAO) that have been cor-
related with fibrosis progression in the kidney  tubulointerstitium11.
At the cellular level, metabolic abnormalities in inflammatory diseases could be related to the nature of the 
immune cell infiltrate and its activation status. For example, macrophage polarization is regulated by glycolysis 
and  FAO13, and T cells reallocate glucose and upregulate glycolysis following  activation14. Moreover, macrophage 
markers have been associated with increased PPP activity in kidney diseases, including lupus nephritis (LN)15. 
Additionally, exhausted T cells with altered mitochondrial function have been found in murine  LN16, and T cells 
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isolated from SLE patients exhibit alterations in lipid  composition17. The idea of targeting T cell metabolism for 
lupus therapy has been  advocated18,19 based on the finding that CD4 T cells in lupus-prone mice had elevated 
glycolysis and oxidative metabolism that could be normalized with metformin and 2-Deoxy-D-glucose (2DG) 
treatment resulting in disease  improvement4.
Taken together, these studies suggest metabolic abnormalities in either infiltrating inflammatory cells or tissue 
cells contribute to and/or reflect tissue damage. To examine this in greater detail, we analyzed gene expression 
profiles in human and murine lupus tissues to discern the nature of abnormal metabolic pathways, elucidate 
cellular origins of metabolic abnormalities, and determine how inflammatory cells contribute to physiologic 
processes involved in tissue inflammation and damage.
Results
Dysregulation of metabolic gene signatures is common among lupus-affected tissues. Despite 
thousands of differentially expressed genes (DEGs) in discoid lupus erythematosus (DLE), World Health Organ-
ization (WHO) class III/IV LN glomerulus (GL) and WHO class III/IV LN tubulointerstitium (TI), there were 
only 559 increased and 324 decreased transcripts in common (Fig. 1a, Supplemental Data S1-S2). Protein–pro-
tein interaction analysis showed the common upregulated genes were related to interferon (IFN) and immune 
signaling pathways (Fig.  1b). The common downregulated genes were related to mitochondrial processes, 
including the TCA cycle and oxidative phosphorylation (OXPHOS).
Figure 1.  Dysregulation of metabolic gene signatures is common among lupus-affected tissues. (a) Comparison 
of DEGs among DLE, class III/IV LN GL, and class III/IV LN TI. (b) MCODE protein–protein interactions of 
common UP and DOWN DEGs were generated with Cytoscape using the STRING and ClusterMaker2 plugins 
and annotated with BIG-C functional categories (odds ratio (OR) > 1, p < 0.05) in Adobe Illustrator. Overlap 
p-value was calculated using Fisher’s exact test. GSVA of signatures for (c) glycolysis, (d) the PPP, (e) the TCA 
cycle, (f) OXPHOS, (g) FAAO, (h) FABO, and (i) AA metabolism in lupus tissues and controls (CTLs). Each 
point represents an individual sample. Significant differences in enrichment of the metabolic signatures in each 
lupus tissue as compared to CTL was determined by Welch’s t-test with Bonferroni correction. Numbers below 
each tissue indicate the number of lupus patients with enrichment scores 1 SD less than (< 1SD) or greater than 
(> 1SD) the CTL mean. For all calculations, the following sample numbers were used: DLE [CTL (n = 8), DLE 
(n = 9)], LN GL [CTL (n = 14), Cl III/IV (n = 22)], and LN TI [CTL (n = 15), Cl III/IV (n = 22)]. **, p < 0.01; ***, 
p < 0.001; ****, p < 0.0001.
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As there is considerable transcriptomic heterogeneity among lupus  patients20,21, we sought to examine expres-
sion of genes controlling metabolism at the individual patient level, and, therefore, employed gene set variation 
analysis (GSVA)22 (Supplemental Data S3). Generally, lupus tissues exhibited lower GSVA scores indicative 
of metabolic pathways, whereas controls had higher metabolism GSVA scores (Fig. 1c–i). The glycolysis and 
OXPHOS signatures were decreased in LN TI, whereas the TCA cycle and fatty acid beta oxidation (FABO) gene 
signatures were decreased in all tissues. Decreases in genes signifying fatty acid alpha oxidation (FAAO) and 
amino acid (AA) metabolism were similarly detected in the majority of lupus patients.
Increased myeloid cell signatures and decreased tissue cell signatures characterize the major-
ity of lupus patients. To determine whether cellular changes accounted for the decreased metabolic signa-
tures, we examined enrichment of immune and non-hematopoietic cell signatures in lupus tissues. Increased tis-
sue enrichment of immune cell signatures was variable, with DLE and LN GL demonstrating more enrichment 
of inflammatory cell signatures as compared to LN TI (Fig. 2a, Supplemental Fig. S1-S2). There was evidence 
of increased plasmacytoid dendritic cell (pDC), dendritic cell (DC), or monocyte/myeloid cell (monocyte/MC) 
signatures in some patients from each tissue. Non-hematopoietic cell gene expression was additionally altered. 
The endothelial cell (EC) signature was increased in LN GL. Keratinocyte transcripts were increased in 4/9 
DLE patients, whereas melanocyte transcripts were decreased in 5/9 patients. General kidney cell transcripts 
Figure 2.  Increased myeloid cell signatures and decreased non-hematopoietic cell signatures characterize 
the majority of lupus patients. (a) Hedges’ g effect sizes of immune and non-hematopoietic cell signatures 
in DLE, class III/IV LN GL, and class III/IV LN TI as compared to tissue CTLs. Significant p-values reflect 
significant differences in enrichment of the immune cell signatures or non-hematopoietic cell signatures in 
lupus tissues as compared to CTL as determined by Welch’s t-test with Bonferroni correction (Supplemental 
Fig. S1). (b)  R2 values derived from linear regression of the monocyte-derived macrophage or the tissue-resident 
macrophage markers with the monocyte/MC GSVA scores in individual patients and CTLs from lupus-affected 
tissues (Supplemental Fig. S3). Significant p-values reflect significantly non-zero slopes. (c) Pearson correlation 
coefficients between tissue-resident macrophage markers in LN. For all calculations, the following sample 
numbers were used: DLE [CTL (n = 8), DLE (n = 9)], LN GL [CTL (n = 14), Cl 3/4 (n = 22)], and LN TI [CTL 
(n = 15), Cl 3/4 (n = 22)]. *, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001.
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were decreased in the majority of LN patients. Genes indicative of podocytes were decreased, whereas genes 
indicative of mesangial cells were increased in LN GL. Finally, the proximal tubule signature was significantly 
decreased and the collecting duct signature was significantly increased in LN TI.
Although the monocyte/MC signature was consistently increased among lupus-affected tissues, its nature in 
each tissue varied. Linear regression of the monocyte/MC signature and FCN1 expression indicated DLE and LN 
GL contained inflammatory monocyte-derived  macrophages23, but the correlation in LN TI was weak (Fig. 2b, 
Supplemental Fig. S3a). Tissue-resident macrophage populations were evaluated in DLE by expression of F13A1, 
FOLR2, SEPP1, and TXNIP24 and in LN by co-expression of CD74 and CD81, which is characteristic of renal 
tissue-resident  macrophages25. The tissue-resident macrophage signature was present in LN TI as evidenced by 
monocyte/MC correlation with both markers and co-expression of CD74 and CD81 (Fig. 2b,c, Supplemental 
Fig. S3b). However, the tissue-resident macrophage signature was not identified in DLE as shown by lack of cor-
relation with F13A1, SEPP1, and TXNIP. Similarly, the tissue-resident macrophage signature was not found in 
LN GL as shown by lack of correlation with CD81 and no co-expression between CD74 and CD81. This suggests 
monocyte/MCs in DLE and LN GL are predominantly infiltrating inflammatory monocyte-derived macrophages, 
whereas LN TI is populated by tissue-resident macrophages.
Class II LN GL is molecularly similar to class III/IV LN GL. To elucidate whether the same metabolic 
signature changes were present in less severe LN, we expanded our analysis to incorporate WHO class II LN 
samples, where less immune cells have been observed  histologically26. Unexpectedly, we found that genes con-
trolling glycolysis, the TCA cycle, FAO, and AA metabolism were decreased in class II LN GL (Fig. 3a–g), and 
gene expression of pDCs and B cells was increased in class II (Fig. 3h–o). It is notable that gene expression of 
non-hematopoietic cell populations was altered in class II LN GL, including a decrease in kidney cell genes and 
an increase in EC genes (Fig. 3p–t). These abnormalities in expression of metabolic genes and non-hematopoi-
etic cell genes were noted even in patients in which an increase in monocyte/MC genes was not detected (Sup-
plemental Fig. S4). Altogether, even though inflammatory cell gene signatures were less pronounced in some 
patients relative to class III/IV, class II LN GL was molecularly similar to class III/IV LN GL (Fig. 3u).
As in the glomerulus, class II LN TI was not statistically different from class III/IV LN TI (Supplemental 
Fig. S5); however, class II LN TI did not display decreased metabolic signatures. Class II LN TI had less indication 
of tissue cell damage and inflammatory infiltrate than class II LN GL (Supplemental Fig. S6).
Cellular signatures are associated with metabolic gene signature dysregulation in 
lupus-affected tissues. Stepwise regression, which identifies the independent variables that best explain 
the dependent  variable27, was employed to analyze cellular signature associations with metabolism gene sig-
nature changes. To improve precision, highly collinear cellular signatures in DLE were combined for stepwise 
analysis (Methods). In DLE, the inflammatory cell, EC, and keratinocyte signatures were positively correlated 
with the glycolysis signature, as indicated by a positive regression coefficient (Supplemental Fig. S7, Supplemen-
tal Data S4). Conversely, the GC B cell and fibroblast signatures were negatively correlated with other metabolic 
signatures. The keratinocyte signature was also negatively correlated with the TCA cycle signature.
We then implemented both stepwise regression and classification and regression tree (CART) analysis, which 
partitions data by independent  variables28, to determine the cellular signatures that were most associated with the 
metabolic signature changes in all classes of LN and controls. In LN GL, all metabolic signatures except for the 
PPP signature exhibited some dependence on the kidney cell signature by either stepwise regression or CART 
(Fig. 4, Supplemental Data S5). The stepwise regression coefficients for the kidney cell signature were positive and 
of the largest magnitude for the TCA cycle, FAAO, FABO, and AA metabolism signatures; a negative regression 
coefficient was noted for the EC signature and glycolysis. Moreover, CART identified the EC signature as the 
strongest contributor to the glycolysis signature, with a positive EC GSVA score predicting a lower glycolysis 
GSVA score. Importantly, the EC signature classifier alone separated 23 of 30 LN GL samples from controls. It 
is notable that by CART analysis upregulation of the monocyte/MC signature tended to mitigate the decreased 
glycolysis signature related to ECs, suggesting that monocyte/MC genes might contribute to glycolysis in opposite 
directions from EC genes. The mocyte/MC signature exhibited a negative stepwise regression coefficient with 
the OXPHOS signature, which was also positively associated with the kidney cell signature by CART. Together, 
the stepwise regression and CART models indicate decreased OXPHOS is reflective of decreased kidney cell and 
increased monocyte/MC signatures, although increased pDC genes may also contribute.
The contribution of kidney-specific cell signatures to most metabolic changes was also observed in the TI 
(Supplemental Fig. S8, Supplemental Data S6). In contrast to LN GL, EC genes did not contribute to the decreased 
glycolysis signature in LN TI, but instead the kidney cell signature was predicted by stepwise regression and 
CART. Numerous cell types were found to contribute to the overall TCA cycle signature. Stepwise regression 
demonstrated a positive contribution from proximal tubule, kidney cell, and granulocyte transcripts, and a 
negative contribution from fibroblast and pDC cell signatures. CART identified the proximal tubule signature 
as the strongest contributor, with a positive correlation to the TCA cycle signature, and confirmed the involve-
ment of the fibroblast signature as well. Monocyte/MC transcripts contributed most to the OXPHOS signature, 
although the regression coefficient was negative, implying that the presence of monocyte/MC contributed to a 
decreased OXPHOS signature. The FABO signature, which has previously been shown to be defective in affected 
TI of multiple  etiologies11,12,29, FAAO, and AA metabolism signatures also demonstrated a positive relationship 
with expression of kidney cell and/or proximal tubule genes.
We sought to confirm these findings by referencing data from single-cell RNA-sequencing (scRNA-seq) of 
LN  biopsies30. In LN, tissue-resident macrophages exhibited decreased OXPHOS genes (Supplemental Fig. S9), 
which aligns with the negative relationship that stepwise regression and CART predicted between the monocyte/
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Figure 3.  Metabolic and cellular signature changes in class II LN GL are similar to those seen in class III/
IV. GSVA of (a–g) metabolic pathway signatures and (h–t) cell signatures in all classes of LN GL. Each point 
represents an individual sample. Significant differences in enrichment of the metabolic signatures, immune cell 
signatures, or non-hematopoietic cell signatures between class II LN GL and CTL, class III/IV LN GL and CTL, 
and class II LN GL and class III/IV LN GL were performed by Welch’s t-test with Bonferroni correction. (u) 
Hierarchical clustering (k = 4) of all glomerular samples. For all calculations, the following sample numbers were 
used: LN GL [CTL (n = 14), Cl II (n = 8), Cl III/IV (n = 22)]. **, p < 0.01; ***, p < 0.001; ****, p < 0.0001.
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MC and OXPHOS signatures in LN TI (Supplemental Fig. S8a and e). Conversely, CD4 T cells had both increased 
and decreased expression of glycolysis genes, making their metabolism difficult to interpret. The kidney epithelial 
cell cluster, which was comprised of general kidney cell as well as tubule genes, exhibited significant negative dif-
ferential expression of two glycolysis genes (G6PC, GAPDH) and one TCA cycle gene (PDK4), but four OXPHOS 
genes were significantly over-expressed (MT-CO2, MT-CO3, MT-ND5, NDUFS3). This supports the idea that 
kidney cells have high oxidative metabolism, and their absence or dysfunction could contribute to decreased 
OXPHOS signatures. However, insufficient genes were detected by scRNA-seq to confirm the current findings 
determined with bulk RNA analysis.
Mitochondrial and peroxisomal signature changes and local hypoxia contribute to changes in 
metabolic gene expression in specific cells. As mitochondria and peroxisomes are the primary orga-
nelles responsible for metabolic processes such as OXPHOS and  FAO31, we sought to examine whether there 
were detectable changes to organelle-specific gene expression that could explain the altered metabolic state. 
Figure 4.  Metabolic gene expression changes in LN GL are associated with changes in the EC, kidney cell, and 
fibroblast gene signatures. (a) Stepwise regression coefficients and (b–h) CART analysis for metabolic pathway 
signatures in all glomerular LN samples and CTLs. Values in the final CART leaves for each process represent 
the average GSVA score of samples that were assigned to that leaf. Each resulting CART decision tree was 
pruned once. For all calculations, the following sample numbers were used: LN GL [CTL (n = 14), Cl II (n = 8), 
Cl III/IV (n = 22)]. Significant p-values in (a) reflect significant coefficients in the stepwise regression model. *, 
p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001.
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There was no evidence of global mitochondrial gene expression changes, although mitochondrial genes were 
decreased in approximately half of DLE patients, and mitochondrial transcription was increased in 15/30 LN GL 
patients (Fig. 5a–e). Conversely, the apoptotic mitochondrial changes signature was increased in both DLE and 
LN GL (Fig. 5f). Genes associated with peroxisome biogenesis were decreased in some lupus patients in each 
tissue; in contrast, genes associated with peroxisomal fission were increased in some class III/IV LN TI patients 
(Fig. 5g–h). Stepwise regression analysis revealed a positive association between the apoptotic mitochondrial 
signature and the granulocyte and inflammatory cell signatures in DLE, and positive associations between the 
apoptotic mitochondrial signature and MC signatures in LN (Fig. 5i–k, Supplemental Data S7-S9). Positive asso-
ciations were observed between the peroxisome biogenesis signature and the kidney cell and proximal tubule 
signatures in LN GL and LN TI, respectively.
Since hypoxia has been cited as a driver of kidney disease in the  TI32, and a hypoxic microenvironment may 
result in decreased oxidative metabolism, we examined the contribution of HIF1A to metabolic gene signatures. 
Some lupus patients had increased expression of HIF1A by GSVA (Fig. 5l). Although HIF1A expression did not 
significantly affect metabolic signatures in DLE, in LN TI, the HIF1A gene signature had a positive correlation 
with the glycolysis signature, whereas in LN GL, the HIF1A gene signature was positively associated with the 
PPP signature (Fig. 5m–o, Supplemental Data S10-S12). This suggests hypoxia contributes to specific metabolic 
alterations in the kidney.
Metabolic gene expression changes occur independent of acute IFN stimulation. The IFN gene 
signature (IGS), a known hallmark of  lupus33,34 and lupus-affected  tissues35, has been implicated in metabolic 
alteration of  MCs36–39. To determine the functional relationship between IFN stimulation and metabolic altera-
tion, we examined metabolic gene expression longitudinally in the IFNα-accelerated NZB/W murine model 
of LN, where the IGS increases at early timepoints following injection of IFNα adenovirus and then increases 
again when kidney disease develops (Fig. 6a). To determine whether metabolic signatures were changed with the 
elevated IGS, we examined metabolic signatures after IFNα administration. No significant changes in metabolic 
signatures were observed at week 1 (W1) after IFNα administration (Fig. 6b–h), the peak of early IGS expression. 
In contrast, the TCA cycle, OXPHOS, FAO, and AA metabolism gene signatures were decreased at W7 post-
IFNα administration, when LN  develops40. There were negative correlations between the IGS and metabolic 
signatures for the TCA cycle, OXPHOS, FAO, and AA metabolism, suggesting increased IFN could contribute 
to decreased metabolism. However, these is a clear separation of the W1 and W7/W9 datapoints in the correla-
tion analysis for TCA cycle, OXPHOS and AA metabolism signatures, in which W1 datapoints show positive 
GSVA scores for both the IGS and metabolic signatures. Thus, based upon the lack of transcriptional metabolic 
changes following early IFN exposure in the mouse, it does not appear that acute exposure to type I IFN explains 
the metabolic changes in lupus tissues, as transcriptional changes to metabolism occur when disease develops 
and the IFN signature reoccurs, but not at W1, W2, or W3
Metabolic and cellular gene expression changes in murine LN are corrected by immunosup-
pressive treatment. To determine the robustness of the observed metabolic and cellular gene expression 
changes and determine whether dysregulation could be reversed by immunosuppressive therapy, we analyzed 
gene expression in pre- and post-treatment kidneys of lupus mice (Supplemental Data S1). Although some 
metabolic changes had previously been identified in the kidneys of untreated and treated NZB/W and NZM2410 
 mice41, no analysis of the nature of the affected cells was carried out.
Metabolic gene expression was significantly altered in NZM2410, NZB/W, IFNα-accelerated NZB/W 
(GSE72410), and NZW/BXSB mice. Treatment of NZM2410 mice with BAFF-R-Ig and proteinuric NZB/W 
mice with a combination of cyclophosphamide (CTX) + CTLA4-Ig + anti-CD154 restored TCA cycle, FAAO, 
FABO, and AA metabolism gene expression (Fig. 7a, b). Notably, in the NZB/W kidneys when combination 
therapy was discontinued and LN relapsed, some metabolic abnormalities recurred. In IFNα-accelerated NZB/W 
mice, both the glycolysis and TCA cycle signatures were significantly decreased with the onset of LN (IFN W7), 
and CTX treatment significantly restored TCA cycle gene expression to baseline pre-disease levels (Fig. 7c). In 
MRL/lpr mice, the same trends were observed, although the data did not achieve statistical significance (Fig. 7d). 
NZW/BXSB mice had decreased metabolic signatures for all processes except glycolysis, the PPP, and OXPHOS 
(Fig. 7e).
GSVA of cellular changes in murine LN models demonstrated similar results to human LN, although inflam-
matory infiltrate and changes in the EC and podocyte signatures were less robust (Supplemental Figs. S10-S15). 
BAFF-R-Ig, combination therapy, and CTX-treatment restored kidney cell and proximal tubule gene signatures, 
and combination therapy decreased inflammatory cell gene signatures. Correlation analysis in all murine LN 
models showed strong positive correlations between metabolism and proximal tubule transcripts, whereas nega-
tive correlations were seen between metabolism and inflammatory cell signatures (Supplemental Fig. S16). This 
suggests that treatment may allow for functional metabolic recovery of non-hematopoietic cells in the kidney 
in the presence or absence of changes to the inflammatory cell signal.
Metabolic changes correlate with expression of genes indicating tubular damage. Finally, we 
examined whether changes in genes controlling metabolism occurred synchronously with changes in expression 
of HAVCR1 (KIM1) and LCN2, which are known markers of tubular  damage42,43. Although HAVCR1 expression 
was increased in class III/IV human LN TI patients, there were no significant changes to LCN2 in any class of 
LN TI (Fig. 8a, b). Similarly, in murine LN models, Havcr1 and Lcn1 expression increased with active disease 
and returned toward normal with treatment. Both markers demonstrated significant inverse correlations with 
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Figure 5.  Mitochondrial and peroxisomal signature changes and local hypoxia contribute to changes in 
metabolic gene expression in specific cells. GSVA of signatures for (a–f) mitochondria- or (g–h) peroxisome-
related gene signatures in lupus tissues and CTLs. Each point represents an individual sample. (i–k) Stepwise 
regression coefficients for mitochondrial and peroxisomal signatures in all tissues and CTLs. (l) GSVA of HIF1A 
in lupus tissues and CTLs. Each point represents an individual sample. (m–o) Stepwise regression coefficients 
for metabolic pathway signatures with the addition of HIF1A in all tissues and CTLsSignificant differences in 
enrichment of the mitochondrial/peroxisomal signatures or HIF1A in DLE and CTL, Cl II LN GL and CTL, Cl 
III/IV LN GL and CTL, Cl II LN TI and CTL, and Cl III/IV LN TI and CTL was determined by Welch’s t-test 
with Bonferroni correction. Numbers below each tissue indicate the number of lupus patients with enrichment 
scores 1 SD less than (< 1SD) or greater than (> 1SD) the CTL mean. For all calculations, the following sample 
numbers were used: DLE [CTL (n = 8), DLE (n = 9)], LN GL [CTL (n = 14), Cl 2 (n = 8), Cl III/IV (n = 22)], 
and LN TI [CTL (n = 15), Cl II (n = 8), Cl III/IV (n = 22)]. Significant p-values in (i–k, m–o) reflect significant 
coefficients in the stepwise regression model. *, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001.
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Figure 6.  Metabolic gene expression changes occur independent of acute IFN stimulation in murine LN. 
GSVA of (a) the IGS in the kidney of IFNα-accelerated NZB/W mice (GSE86423). (b–h) GSVA of metabolic 
signatures and linear regression between the IGS and metabolic signature GSVA scores. Each point represents 
an individual mouse. For each signature, significant differences in enrichment at each timepoint compared to 
baseline were evaluated with the Mann–Whitney U test. For all calculations the following sample numbers were 
used: Baseline (n = 3), W1 (n = 5), W2 (n = 5), W3 (n = 5), W5 (n = 5), W7 (n = 5), and W9 (n = 5). Significant 
p-values in the regression plots in (b–h) reflect significantly non-zero slopes. *, p < 0.05; **, p < 0.01; ***, 
p < 0.001; ****, p < 0.0001.
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Figure 7.  Metabolic gene expression changes in murine LN are corrected with immunosuppressive treatment. 
GSVA of metabolism signatures in the kidney of (a) NZM2410 (GSE32583, GSE49898), (b) NZB/W (GSE32583, 
GSE49898), (c) IFNα-accelerated NZB/W (GSE72410), (d) MRL/lpr (GSE153021), and (e) NZW/BXSB 
(GSE32583, GSE49898) mice with and without treatment. Each point represents an individual mouse. For each 
signature, significant differences in enrichment at each timepoint compared to baseline and each treatment 
timepoint compared to disease were evaluated with the Mann–Whitney U test. For all calculations the following 
sample numbers were used: NZM2410 [6w (n = 5), 21-30w (n = 5), Tx + 15w (n = 6)], NZB/W [16w (n = 8), 23w 
(n = 6), 36w (n = 10), Tx Remission + 3-4w (n = 8), Tx Remission +  > 5w (n = 6)], IFN-accelerated NZB/W [Naïve 
(n = 5), IFN W3 (n = 5), IFN W7 + Veh (n = 5), IFN W7 + CTX (n = 5)], MRL/lpr [Wildtype (n = 3), Vehicle 
(n = 3), Prednisone (n = 3), MMF (n = 3), FK506 (n = 3), Multi-target (n = 3)], and NZW/BXSB [17w (n = 6), 
18-21w + proteinuria (P) (n = 6)]. *, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001.
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Figure 8.  Cellular and metabolic gene expression changes correlate with expression of genes indicating tubular 
damage in human and murine LN. Log2 expression of (a) HAVCR1/Havcr1 and (b) LCN2/Lcn2 in human LN 
TI and the kidneys of (NZM2410 (GSE32583, GSE49898), NZB/W (GSE32583, GSE49898), IFNα-accelerated 
NZB/W (GSE86423), IFNα-accelerated NZB/W (GSE72410), and MRL/lpr (GSE153021) mice. Each point 
represents an individual human or mouse. Significant differences in gene expression at each timepoint compared 
to disease were evaluated in the human TI with Welch’s t-test and in murine models with the Mann–Whitney 
U test. Linear regression between HAVCR1/Havcr1 and LCN2/Lcn2 expression and kidney cell, proximal 
tubule, and TCA cycle GSVA scores in all samples for (c–e) human and (f) murine LN. For all calculations the 
following sample numbers were used: LN TI [CTL (n = 15), Cl II (n = 8), Cl III/IV (n = 22)], NZM2410 [6w 
(n = 5), 21-30w (n = 5), Tx + 15w (n = 6)], NZB/W [16w (n = 8), 23w (n = 6), 36w (n = 10), Tx Remission + 3-4w 
(n = 8), Tx Remission +  > 5w (n = 6)], IFN-accelerated NZB/W (GSE86423) [Baseline (n = 3), W1 (n = 5), W2 
(n = 5), W3 (n = 5), W5 (n = 5), W7 (n = 5), and W9 (n = 5)], IFN-accelerated NZB/W (GSE72410) [Naïve 
(n = 5), IFN W3 (n = 5), IFN W7 + Veh (n = 5), IFN W7 + CTX (n = 5)], and MRL/lpr [Wildtype (n = 3), Vehicle 
(n = 3), Prednisone (n = 3), MMF (n = 3), FK506 (n = 3), Multi-target (n = 3)]. Significant p-values in (c–f) reflect 
significantly non-zero slopes determined by linear regression or correlation analysis. *, p < 0.05; **, p < 0.01; ***, 
p < 0.001; ****, p < 0.0001.
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the kidney cell, proximal tubule, and TCA cycle signatures in both human and murine LN, although there were 
model-dependent differences in magnitude (Fig. 8c–f, Supplemental Fig. S17).
Discussion
Multi-pronged bioinformatic analyses of gene expression data from human lupus tissues revealed that despite 
intra-tissue heterogeneity metabolic dysfunction was present in all tissues. Immune effector cells have high 
metabolic  needs13,14,44,45 and, therefore, we initially hypothesized immune infiltration may be responsible for the 
observed lupus tissue-wide metabolic dysregulation. Although kidney-infiltrating CD8 T cells in murine LN are 
functionally exhausted with defective  mitochondria16, anergic/activated T cell markers were not found in these 
human LN samples, and regression models indicated T cells contributed minimally to changes in renal metabolic 
gene expression. Similarly, monocyte/MCs, which were increased in some patients from all tissues, might be 
expected to contribute to enhanced glucose metabolism – either glycolysis (M1 macrophages) or OXPHOS (M2 
macrophages)44. Indeed, monocyte/MC signatures were inversely correlated with OXPHOS in both LN tissues, 
and positively correlated with glycolysis in LN GL, suggesting they are likely M1 in nature and may contribute to 
the altered metabolic landscape of intact tissues. Although gene expression revealed differing origins of the renal 
MC populations, as they reflect monocyte-derived macrophages in LN GL and tissue-resident macrophages in 
LN TI, the consistent MC presence aligns with their prominent role in tissue  damage46. Observed increases in 
the monocyte/MC signature and strong inverse correlations between MCs and metabolism may reflect the role 
of MCs in tissue damage, even when T and B cells are not yet abundant.
To examine whether metabolic abnormalities represented primarily tissue cell defects as opposed to changes 
in inflammatory cell metabolism, we analyzed gene expression in class II LN, in which less inflammatory infiltrate 
is evident  histologically26. Even though class II LN samples had evidence of increased immune/inflammatory cell 
signatures that coincided with changes to metabolic signatures, examples were observed in which the changes in 
metabolic signatures were found in the absence of a monocyte/MC signature, suggesting alterations in metabolic 
signatures may be initiated immediately following immune complex (IC) deposition and complement activation. 
Subsequent monocyte/MC and other inflammatory cell activation/infiltration may then contribute to further 
damage of tissue cells. Indeed, previous studies report that changes in kidney gene expression can occur follow-
ing early IC deposition, but before microscopic detection of  inflammation47, consistent with our transcriptomic 
results in class II LN.
Our findings of altered metabolism in lupus tissues align with changes seen in other forms of tissue pathol-
ogy. We observed a positive association between the keratinocyte and glycolysis signatures, and upregulation of 
glycolysis has been observed in keratinocytes during cutaneous  infection48. Increased  glycolysis49,50 and decreased 
PPAR signaling, TCA cycle, and OXPHOS have been reported in dermal fibroblasts subjected to  radiation50, 
indicating dermal fibroblasts have the potential to contribute to inflammation-induced alterations in metabo-
lism. However, in the current study, stepwise regression indicated that the fibroblast signature was negatively 
associated with the glycolysis, PPP, and OXPHOS signatures, whereas associations with FAO did not achieve 
statistical significance. The negative correlation between the fibroblast and PPP signatures contrasts with the 
observed upregulation of the PPP in cultured fibroblasts and keratinocytes that were exposed to UV-induced 
oxidative  stress8. This suggests that in vivo fibroblasts are altered by signals different than that mediated by UV 
light, as expected since fibroblasts are deep in the dermis and shielded from such ambient exposure.
Metabolic dysregulation is also common in kidney  disease12,15,29,51,52. In non-diabetic chronic kidney disease, 
TCA cycle abnormalities measured in urine metabolites coincided with changes to kidney gene  expression51, 
supporting our conclusions that metabolic dysregulation primarily reflects altered renal cell function as opposed 
to changes in immune cell metabolism. Moreover, defects in FAO have been correlated with fibrosis progression 
in TI  disease11. Both human and murine models with TI fibrosis exhibited decreased expression of FAO enzymes 
and resultant increases in lipid deposition, which was reversed by correcting the metabolic  abnormalities11. We 
similarly found that FAO signatures aresubstantially decreased in the TI; however, regression models indicated 
that altered FAO transcripts were most associated with decreased kidney cell signatures. Although fibroblasts 
were not predicted by the models, fibrosis or fibroblast enrichment could contribute to decreased kidney cell 
and proximal tubule transcripts in the TI.
In the glomerulus, ECs appear to play an additional role in disease. Endothelial activation in LN has been 
suggested  previously53, and EC transcripts were increased in 83% of all LN GL samples. Increased EC tran-
scripts may reflect altered EC function, potentially resulting from cytokine/growth factor stimulation and/or 
hypoxia-induced cellular damage. Abnormal angiogenesis has been reported in diabetic nephropathy resulting 
in leaky  vessels54, but the function of glomerular ECs in LN is less well-defined. Indeed, glomerular ECs have 
been found to be dependent upon podocyte stimulation for  differentiation55, whereas other studies suggest EC 
damage precedes podocyte  injury56. Our findings from class II LN support the latter, as signature changes to ECs 
occurred in the absence of podocyte changes in some patients, suggesting that ECs are early participants in LN.
The relationship between the EC signature and metabolic gene expression changes implied an alteration in EC 
physiology in LN. Although healthy ECs are highly  glycolytic57, all regression techniques in LN GL indicated an 
inverse correlation between the EC and glycolysis signatures. Consistent with our findings, in diabetic nephropa-
thy stalled glycolytic flux has been observed in  ECs57. These data suggest that glomerular ECs are metabolically 
altered, perhaps because of IC and complement stimulation and/or cytokine exposure, making them less capable 
of maintaining normal function. Indeed, in the GL, the EC signature had a positive regression coefficient with 
the FABO signature, and quiescent ECs have been reported to upregulate  FABO58, supporting the conclusion 
that ECs are functionally deranged in LN GL.
Analysis of metabolism-associated genes in cell clusters derived from scRNA-seq of LN  biopsies30 further 
supports our finding that changes in metabolism are most closely related to kidney cell gene expression, with 
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minor contributions from resident or infiltrating immune cells. Tissue-resident macrophages exhibited decreased 
OXPHOS genes, whereas CD4 T cell metabolism was unclear. Notably, the kidney epithelial cell cluster reported 
many metabolism-associated genes, suggesting decreased glycolysis and TCA cycle, but increased OXPHOS. 
Proximal tubules, which have the most mitochondria of any kidney epithelial cell, are known to be dependent on 
oxidative  metabolism59, and this further supports the idea that diminished OXPHOS in bulk RNA in part reflects 
decreased kidney epithelial cell transcripts. Additionally, because scRNA-seq looks at expression of individual 
cells as opposed to the bulk environment, the detected kidney epithelial cells are likely the residual functionally 
normal ones. However, because of technical issues including cell yield and read depth, there are difficulties in 
determining the status of individual cell metabolism from the scRNA-seq data. Altogether, scRNA-seq appeared 
to be less effective than deconvolution of bulk RNA to detect important but subtle changes in cellular metabolism.
To determine whether defective organelles were responsible for metabolic alteration, we examined gene 
expression specific for both mitochondrial and peroxisomal function. We observed changes to the mitochondrial 
and peroxisomal gene signals in some patients, and correlation analysis suggested these changes were associated 
with specific cell types. Notably, the peroxisome biogenesis signature was positively associated with signatures 
for ECs, kidney cells, and proximal tubules. Moreover, as the kidney is highly susceptible to  hypoxia60, we 
investigated the propensity for hypoxia to contribute to altered metabolism. Although GSVA demonstrated no 
significant increases in HIF1A expression, there was an association between HIF1A and the PPP and glycolysis 
signatures in LN GL and LN TI, respectively, suggesting that hypoxia can have specific effects on metabolism, 
and may contribute to some of the metabolic changes observed in the tissues.
The relationship between the IGS and metabolic signature changes in IFNα-accelerated LN mice indicated that 
acute type I IFN exposure could not explain the observed metabolic changes. The mouse studies were particularly 
informative because IFNα exposure was regulated. Although it has been demonstrated that type I IFN stimulation 
can increase OXPHOS and FAO in DCs and  MCs36,38, inhibit isocitrate dehydrogenase (part of the TCA cycle) in 
 macrophages39, and alter oxidative metabolism in other  cells61, IFNα overexpression did not change metabolic 
signatures at early timepoints. However, there was an inverse relationship between the IGS and metabolic defects 
after LN onset, when the IGS recurred. These results support the conclusion that downregulation of metabolic 
pathways is unlikely to be explained by the known actions of type I IFN alone, but rather during LN progres-
sion, decreased metabolic signatures may be parallel reflections of continued IGS exposure and inflammation.
Metabolic gene expression was altered in four murine LN models and immunosuppressive treatment, not 
known to directly affect cellular metabolism, restored metabolic gene expression. Although combination therapy 
diminished inflammatory cell abundance in the kidneys of NZB/W mice, we also observed restoration of meta-
bolic and kidney cell gene expression after treatment in models with little inflammatory infiltrate or those in 
which inflammatory cells were not significantly decreased with treatment. This suggests that although inflam-
matory cells play a critical role in mediating tissue cell damage and metabolic dysfunction, damage is not related 
only to local inflammatory cells, as intensive therapy with CTX restores tissue cell defects without significant 
changes to inflammatory cells. Importantly, these results demonstrate that metabolic abnormalities in tissue 
cells are reversible with immunosuppressive therapy and restored metabolic gene expression might be consid-
ered a goal of effective lupus treatment. Moreover, monitoring tissue metabolism may be especially important 
in situations where anti-metabolic drugs, such as metformin or 2DG, are employed. Whereas these drugs may 
be promising for correction of individual immune cell defects, they have potential consequences for already 
metabolically deranged tissue cells.
Additionally, these studies reveal subtle differences in pathology of glomerular and tubulointerstitial involve-
ment in LN. In both kidney regions, we observed decreased resident non-hematopoietic cell signatures and 
increased monocyte/MC signatures. However, monocyte/MCs in the glomerulus were likely monocyte-derived, 
whereas those in the tubulointerstitium appeared more like tissue-resident macrophages. Moreover, tubuloint-
erstitial diseases in class III/IV LN was characterized by less inflammatory infiltrate than was observed in the 
glomerulus, and although metabolic signatures were comparably decreased in all classes of glomerular LN, 
metabolic signature changes in class II tubulointerstitial LN were less consistently regulated. These results align 
with studies that show tubulointerstitial damage occurs later in LN and predicts end stage renal  disease62. Poorer 
outcomes in class III/IV could be related to persistence of abnormalities or inhibition of repair mechanism that 
might contribute to progressive renal disease. Nonetheless, it is noteworthy that even the more modest immu-
nologic damage in class II LN was associated with marked changes in metabolic signatures.
Detectable changes to immune cell, EC, kidney cell, and metabolic gene signatures in all classes of LN GL is 
notable. We found that gene expression may detect cellular changes with greater sensitivity than immunohis-
tochemistry, when little or no inflammatory infiltrate is observed histologically. Gene expression may provide 
an advance to current classification or diagnostic techniques, as gene expression changes are detectable before 
discernable immunohistochemical changes, and transcriptomic analysis of metabolism can elucidate potential 
functional rather than merely histopathologic changes.
Our study is not without limitations. We performed post-hoc analysis of bulk gene expression in three lupus-
affected tissues comprising limited numbers of lupus patients. Moreover, 37.5% of LN patients were being treated 
with  immunosuppresives53, that may have affected gene signatures. Additionally, the gene signature we identi-
fied as reflecting general kidney cells may be more specific for tubule cells, despite the strong representation in 
the glomerulus. Furthermore, regression analyses provided an estimate of the cellular variables that are most 
associated with each metabolic signature, but accuracy can be limited by sample size, and there is a chance of 
overfitting. Future work with larger cohorts currently not available would be necessary to validate these results. 
Additionally, direct assessment of functional metabolism may be necessary to assay how metabolic changes at 
the gene expression level reflect changes in protein content and cellular function.
In conclusion, prominent alterations in cellular metabolism signatures are characteristic of lupus tissue pathol-
ogy. Systems bioinformatics and assessment with regression modeling techniques revealed that the monocyte/
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MC signature, including both monocyte-derived macrophages and tissue-resident macrophages, was increased 
in many lupus patients, kidney cell signatures were decreased in LN, the EC signature was increased in LN GL, 
and these cell signature changes were associated with altered metabolism signatures. Moreover, apoptotic mito-
chondrial gene changes were associated with MC genes in DLE and LN GL. In murine LN, metabolic dysregula-
tion correlated with tubular damage marker expression and metabolic gene changes were reverted to normal by 
immunosuppressive therapy. Altogether, altered metabolism may serve as a promising biomarker or therapeutic 
target for lupus tissue disease, especially as metabolic gene expression changes precede expression of the renal 
damage biomarker LCN2 in human LN, and coincide with changes to HAVCR1. Indeed, urinalysis has been used 
to measure metabolite biomarkers in the  kidney51,52 and metabolism transcripts could be used to estimate degree 
of kidney cell damage and assess treatment efficacy. Although treatment strategies aimed at metabolic restoration 
are not straightforward, the current findings support the conclusion that immunosuppressive therapy can restore 
metabolic function, and, thereby, may ameliorate damage in specific lupus-affected tissues.
Methods
Human and mouse gene expression datasets. Raw data from publicly available human and murine 
lupus datasets were derived from the Gene Expression Omnibus (GEO) repository. All datasets are summarized 
in Supplemental Data S1.
GSE72535 comprises microarray analysis of lesional skin biopsies from human patients with DLE with no 
systemic involvement with Cutaneous Lupus Activity and Severity Index (CLASI) ≥  263. Some DLE patients 
were treated with various therapies including corticosteroids, immunomodulators, and  hydroxychloroquine63.
GSE32591 consists of microarray analysis of human renal biopsies that were originally derived from the 
European Renal cDNA Bank (ERCB)53. LN patients from the ERCB (n = 32) had an average age of 35.1 ± 2.4 years, 
average proteinuria of 2.9 ± 0.6 g/day, and  eGFRMDRD of 63.7 ± 5.4 ml/min/1.73m2. LN patients were treated with 
various therapies, including steroids and  immunosuppressants53. Two patients from this group were excluded 
from our analyses because they had non-inflammatory class V LN.
GSE86423 consists of samples from the IFNα-accelerated NZB/W LN model. Female NZB/W mice were 
injected with an adenovirus vector expressing recombinant murine IFNα (5 ×  109 particles) at 9  weeks40. Kidney 
gene expression was measured in mice at 0, 1, 2, 3, 4, 5, 7, and 9 weeks post IFNα  injection40.
GSE32583 and GSE49898 consist of samples from three murine lupus models. Kidney gene expression was 
measured in NZM2410 mice including 6–8 week pre-disease mice, 22–30 week diseased mice, and treated mice 
in remission (Tx + 15w)41,53. NZM2410 mice in the Tx + 15w group were treated with adenovirus expressing 
BAFF-R-Ig at 22 weeks, and then sacrificed at 30–35 weeks or 55  weeks41. Kidney gene expression in NZB/W mice 
was measured at 16w, 23w, 36w, and after  treatment41,53. Both 23w and 36w mice shown in the main figures had 
confirmed proteinuria. Some NZB/W mice with proteinuria (> 300 mg/dl) at two timepoints were treated with 
combination therapy – one dose of 50 mg/kg CTX, six doses of 100 µg CTLA-4-Ig, and one dose 250 µg of anti-
CD40L41. Mice were determined to be in remission if they achieved proteinuria of ≤ 30 mg/dl at two  timepoints41. 
One group was sacrificed 3–4 weeks after remission (Tx Rem. + 3-4w) and another was sacrificed > 5–14 weeks 
after remission (Tx Rem.+  > 5w)41. The latter group had confirmed histologic  relapse41. Kidney gene expression 
from NZW/BXSB mice was measured at 17w (prenephritic mice) or 18-21w mice with confirmed  proteinuria53.
GSE72410 comprises samples from the IFNα-accelerated NZB/W LN model. NZB/W mice were treated 
with adenovirus-expressing murine IFNα at 14-15w (1.2 × 108 IFNα rAd5-CMV)64. Kidney gene expression 
was measured in 17w naïve NZB/W (naïve), as well as IFNα-accelerated NZB/W mice: 17w mice 21 days post 
IFNα injection (IFN W3), and in mice treated with vehicle or CTX for four weeks beginning three weeks post 
IFNα njection (IFN W7 + Veh or IFN W7 + CTX)64.
GSE153021 consists of samples from the MRL/lpr LN model. MRL/lpr mice were treated with vehicle, pred-
nisone, mycophenolate mofetil (MMF), FK506, or all three (Multi-target) for eight weeks beginning at week 8 
or age-matched wildtype MRL/MpJ mice treated with  vehicle65.
Quality control and data normalization. Microarray data were processed as previously  described66 
using free, open source programs (GEOquery, affy, affycoretools, limma, and simpleaffy). Unnormalized arrays 
were inspected for visual artifacts or poor RNA hybridization using QC plots. Datasets were annotated using 
their native chip definition files (CDFs). Probes missing gene annotation data were discarded. Raw data (CEL 
files) from the Affymetrix platform were background corrected and normalized using guanine cytosine robust 
multiarray average (GCRMA) or robust multichip average (RMA) algorithms, whereas raw data files from Illu-
mina chip were read and normalized using neqc (limma R package).
RNA-seq data (GSE72410 and GSE153021) was processed from FASTQ files as previously described by 
Daamen et al.67 and also described below. SRA files were downloaded and converted into FASTQ format. Read 
ends and adapters were trimmed with Trimmomatic (v0.38) using a sliding window, ilmnclip, and headcrop 
filters. The reads were head cropped at 6 bp and adapters were removed before read alignment. Reads were 
mapped to the mouse reference genome m17 using STAR, and the .sam files were converted to sorted .bam files 
using Sambamba. The mouse reference genome was downloaded from GENCODE. Read counts were summa-
rized using the featureCounts function of the Subread package (v1.61). The DESeq2 workflow was used to filter 
RNA-seq genes with low expression (i.e. genes with very few reads). The filtered raw counts were normalized 
using DESeq method and then log2 transformed.
Principal component analysis was used to inspect the raw data files from each dataset for outliers. All log2 
transformed data was formatted into R expression set objects (E-sets).
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DEG analysis. For human dataset DEG analysis, Affymetrix probes were additionally annotated with cus-
tom BrainArray (BA) chip definition files (CDFs)68 as previously  described66. Any probes with different Affym-
etrix and BA gene annotations were excluded. GCRMA-normalized expression values were variance corrected 
using local empirical Bayesian shrinkage before calculation of DEGs using the ebayes function in the BioCon-
ductor LIMMA package. P-values were adjusted for multiple hypothesis testing using the Benjamini–Hochberg 
correction, which resulted in a False Discovery Rate (FDR). Significant Affymetrix and BA probes within each 
study were merged and filtered to retain probes with a pre-set FDR < 0.2 which were considered statistically 
significant. This FDR was employed to avoid falsely excluding genes of interest. This list was further filtered to 
retain only the most significant probe per gene in order to remove duplicate genes.
Network analysis and visualization. Cytoscape (V3.8.0)69 with the Search Tool for the Retrieval of 
Interacting Genes/Proteins (STRING) (V1.5.1) and ClusterMaker2 (V1.3.1)70 plugins was used to create and 
visualize protein–protein interactions among the 883 common DEGs. Clusters were generated with the Molecu-
lar Complex Detection (MCODE) clustering algorithm within ClusterMaker2 and a node score cutoff of 0.2, 
k-Core of 2, and a max depth of 100 were set.
Functional enrichment analysis. Functional enrichment of Cytoscape-derived MCODE clusters was 
performed using BIG-C, a clustering tool developed to categorize the biologic function of large lists of  genes66. 
The top three significant BIG-C categories (p < 0.05, OR > 1) were reported.
Gene set variation analysis (GSVA). GSVA22 for R/Bioconductor was used as a non-parametric, unsu-
pervised method for estimating the variation of pre-defined gene sets in dataset samples. For each dataset only 
one CDF, Affymetrix or Illumina, was used for each probe. For genes with multiple Affymetrix probe identifiers, 
only the probe with the highest inter-quartile range (IQR) of  expression71 was retained. Genes with IQR = 0 were 
removed. GSVA enrichment scores were calculated non-parametrically using a Kolmogorov Smirnoff (KS)-like 
rank  statistic22; a negative value for a particular sample and gene set means that the gene set has a lower expres-
sion than the gene set with a positive value. The same GSVA probes used in calculations for class III/IV LN GL 
and TI were specified for calculations in all classes of LN.
GSVA gene sets. Metabolism gene sets were created from literature mining. Hematopoietic gene sets were 
derived from Immune/Inflammatory-Scope (I-Scope), a tool developed to identify immune cell-specific genes 
in big  data72. Non-hematopoietic cellular gene sets were derived from T-Scope72 or literature mining. Many gene 
sets in T-Scope were derived from The Human Protein Atlas (https:// www. prote inatl as. org)73,74. The keratinocyte 
signature was derived from the keratinocyte-specific genes of Gazel et al.75. Kidney-specific lists generated from 
the Human Protein Atlas and single-cell data were additionally modified to incorporate genes found by both 
transcriptomics and  immunohistochemistry76. The mesangial cell signature was derived from  PanglaoDB77. In 
all tissues, the hematopoietic, EC, and fibroblast gene sets were evaluated. For non-hematopoietic gene signa-
tures, those relevant to each tissue were reported (DLE—keratinocyte, melanocyte; LN GL—kidney cell, podo-
cyte, mesangial cell; LN TI—kidney cell, proximal tubule, Loop of Henle (LoH) cell, distal tubule, collecting duct 
cell). Mitochondrial and peroxisomal gene sets were derived from literature mining and the BIG-C, and also 
compared to signatures in the MSIG database. The Apoptotic Mitochondrial Changes signature (M7482) was 
accessed on the MSIG  database78,79 and is derived from GO_0008637. GO_Mitochondrial_Fission (M12786) 
and GOBP_Peroxiome_Fission (M22828) signatures were accessed on the MSIG database and modified slightly. 
The IGS is the type I IFN core signature previously  reported35.
All human metabolism, non-hematopoietic cell, and IFN gene sets were converted to murine gene sets using 
the homologene R package and human2mouse function. Genes that were not converted programmatically were 
manually converted by GeneCards and Mouse Genome Informatics orthologs. Murine hematopoietic cell gene 
sets were curated by literature mining. For murine datasets with expression of two or more anergic/activated 
T cell markers, the aergic/activated T cell signature was combined with the T cell signature for GSVA analysis.
Although the same gene sets were input for each category in each tissue (Supplemental Data S3), the genes 
used in calculation of the GSVA enrichment score for each tissue differ slightly based upon the gene measure-
ment platform and expression within that sample. All reported GSVA enrichment scores, except for the HIF1A 
gene signature, were calculated based upon a minimum of three genes. The HIF1A gene signature only includes 
HIF1A because there were no additional genes determined to be specific to hypoxia only. Although two genes 
were well co-expressed, the DC signature in LN TI did not meet the minimum three gene requirement for GSVA, 
nor did the LDG signature in LN GL and LN TI.
Hierarchical clustering. Human lupus tissue samples were hierarchically clustered by the Euclidian dis-
tance of their GSVA enrichment scores into two (k = 2) or four (k = 4) clusters using the heatmap.2 function in R.
Regression models. For all linear models, GSVA scores for cellular signatures in all tissue samples were 
input as independent variables, and the pathway GSVA score (metabolism signature, mitochondrial signature, or 
peroxisomal signature) was input as the dependent variable. As GSVA scales the expression of a signature from 
-1 to -1, the value for each input cellular or metabolic signature in each sample is relative to the same signature 
in other samples and to the other signatures in the same sample. To ensure that collinearity between immune cell 
signatures did not confound results for stepwise regression analyses in DLE, we combined the pDC, skin-specific 
DC, monocyte/MC, T cell, anergic/activated T cell, B cell, and plasma cell signatures into the “inflammatory 
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cell” signature, because the genes were highly co-expressed. The list of all genes used as the “inflammatory cell” 
signature can be found in Supplemental Data S3. This reduced the number of input variables for DLE stepwise 
analysis to ten cell signatures.
Visualization. Final figures were generated in GraphPad Prism or Adobe Illustrator.
Statistics. Overlap p-values and ORs for functional enrichment of DEGs were calculated in R using two-
sided fisher.test with confidence level = 0.95. Because of known heterogeneity in lupus patients, the number of 
lupus patients in each tissue who fell above or below the control mean ± 1 standard deviation (SD) were then 
reported in order to determine whether individual patients exhibit an increased or decreased signature when 
the population did not achieve statistical significance. Calculation of mean and standard deviation (SD) for the 
control samples for each GSVA score in each tissue was performed in Microsoft Excel. All analyses in GraphPad 
Prism were carried out with version 8.2.0 (435) or later versions. Control and lupus sample populations of GSVA 
scores for each gene set were assessed for normality using the D’Agostino-Pearson test in GraphPad Prism and 
the distributions for 75% or more of the gene sets in each population were determined to be normal. Welch’s 
t-test with Bonferroni correction for GSVA enrichment in human samples was performed in GraphPad Prism. 
Bonferroni correction for metabolic signatures, immune cell signatures, non-hematopoietic signatures, or mito-
chondrial/peroxisomal signatures were performed separately. The Mann–Whitney U test for GSVA enrichment 
in murine samples was performed in GraphPad Prism. Univariate (simple) linear regression and Pearson corre-
lation analyses were carried out in GraphPad Prism. Hedges’ g effect sizes were calculated in R using the cohen.d 
function with Hedges’ correction under the “effsize” package. Stepwise regression was performed in R using the 
lm function followed by the stepAIC function. Variance inflation factor (VIF) < 10 was confirmed for each inde-
pendent variable (Supplemental Data S4-S12). Although some data points were determined to be influential to 
the stepwise equation using Cook’s D, no samples were removed from the models in efforts to capture the hetero-
geneity present in lupus. CART analysis was performed in R using the rpart function with the “anova” method. 
Each resulting decision tree was pruned once except for the glycolysis and PPP signatures in LN TI. GSVA scores 
for all individual samples (patient or control) are presented as individual data points in either dot or violin plots. 
The number of samples for each group can be found in Supplemental Data S1 and the figure legends. Informa-
tion regarding the statistical comparisons made and level of significance is mentioned in the figure legends.
Data availability
All microarray datasets in this publication are available on NCBI’s GEO database (Supplemental Data S1). All 
bioinformatic software used in this publication is open source, and freely available for R. Example codes used in 
this paper (LIMMA, GSVA, stepwise regression, and CART) are available at figshare, https:// www. figsh are. com 
as “AMPEL BioSolutions LIMMA Differential Expression Analysis Code,” “AMPEL BioSolutions GSVA AFFY 
nonzeroIQR Code”, and “AMPEL BioSolutions Stepwise and CART Code,” respectively.
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